Fragile X Syndrome – Pipeline Review, H2 2012
SUMMARY
Global Markets Direct’s, 'Fragile X Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
SUMMARY
Global Markets Direct’s, 'Fragile X Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
- A snapshot of the global therapeutic scenario for Fragile X Syndrome.
- A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Fragile X Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Fragile X Syndrome
Fragile X Syndrome Therapeutics under Development by Companies
Fragile X Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Fragile X Syndrome Therapeutics – Products under Development by Companies
Fragile X Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Fragile X Syndrome Therapeutics Development
F. Hoffmann-La Roche Ltd.
XenoPort, Inc.
Novartis AG
Sigma-Tau S.p.A.
Paratek Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc.
Seaside Therapeutics
Snowdon Inc.
Marinus Pharmaceuticals, Inc.
Nexgenix Pharmaceuticals, LLC
aFraxis Inc.
Fragile X Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
mavoglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-929 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7090 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTK-MS-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pak Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
donepezil hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Program For Neurological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate Prodrug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAK Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ampakine + mGluR5 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mGluR5 Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Fragile X Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fragile X Syndrome Therapeutics – Drug Profile Updates
Fragile X Syndrome Therapeutics - Dormant Products
Fragile X Syndrome – Product Development Milestones
Featured News & Press Releases
Sep 19, 2012: Seaside Therapeutics Publishes Seminal Research Supporting Disease-Modifying Potential Of STX209 In Fragile X Syndrome
Jun 02, 2011: Seaside Therapeutics Initiates Pivotal Phase III Study Of STX209 In Fragile X Syndrome
Apr 13, 2011: Marinus Receives US Department Of Defense Grant To Study Ganaxolone In Fragile-X Syndrome
Jul 26, 2010: Seaside Reports Data From Phase II Study Of STX209 In Patients With Fragile X Syndrome
Jul 23, 2010: Xenoport Announces Presentation Of Preclinical Data For Acamprosate Prodrug At Fragile X Syndrome Conference
Nov 02, 2009: Seaside Therapeutics Initiates Clinical Development of STX107 For Fragile X Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Fragile X Syndrome, H2 2012
Products under Development for Fragile X Syndrome – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
XenoPort, Inc., H2 2012
Novartis AG, H2 2012
Sigma-Tau S.p.A., H2 2012
Paratek Pharmaceuticals, Inc., H2 2012
Cortex Pharmaceuticals, Inc., H2 2012
Seaside Therapeutics, H2 2012
Snowdon Inc., H2 2012
Marinus Pharmaceuticals, Inc., H2 2012
Nexgenix Pharmaceuticals, LLC, H2 2012
aFraxis Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Fragile X Syndrome Therapeutics – Drug Profile Updates
Fragile X Syndrome Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Fragile X Syndrome, H2 2012
Products under Development for Fragile X Syndrome – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Fragile X Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Fragile X Syndrome
Fragile X Syndrome Therapeutics under Development by Companies
Fragile X Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Fragile X Syndrome Therapeutics – Products under Development by Companies
Fragile X Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Fragile X Syndrome Therapeutics Development
F. Hoffmann-La Roche Ltd.
XenoPort, Inc.
Novartis AG
Sigma-Tau S.p.A.
Paratek Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc.
Seaside Therapeutics
Snowdon Inc.
Marinus Pharmaceuticals, Inc.
Nexgenix Pharmaceuticals, LLC
aFraxis Inc.
Fragile X Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
mavoglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-929 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7090 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTK-MS-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pak Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
donepezil hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Program For Neurological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate Prodrug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAK Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ampakine + mGluR5 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mGluR5 Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Fragile X Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fragile X Syndrome Therapeutics – Drug Profile Updates
Fragile X Syndrome Therapeutics - Dormant Products
Fragile X Syndrome – Product Development Milestones
Featured News & Press Releases
Sep 19, 2012: Seaside Therapeutics Publishes Seminal Research Supporting Disease-Modifying Potential Of STX209 In Fragile X Syndrome
Jun 02, 2011: Seaside Therapeutics Initiates Pivotal Phase III Study Of STX209 In Fragile X Syndrome
Apr 13, 2011: Marinus Receives US Department Of Defense Grant To Study Ganaxolone In Fragile-X Syndrome
Jul 26, 2010: Seaside Reports Data From Phase II Study Of STX209 In Patients With Fragile X Syndrome
Jul 23, 2010: Xenoport Announces Presentation Of Preclinical Data For Acamprosate Prodrug At Fragile X Syndrome Conference
Nov 02, 2009: Seaside Therapeutics Initiates Clinical Development of STX107 For Fragile X Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Fragile X Syndrome, H2 2012
Products under Development for Fragile X Syndrome – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
F. Hoffmann-La Roche Ltd., H2 2012
XenoPort, Inc., H2 2012
Novartis AG, H2 2012
Sigma-Tau S.p.A., H2 2012
Paratek Pharmaceuticals, Inc., H2 2012
Cortex Pharmaceuticals, Inc., H2 2012
Seaside Therapeutics, H2 2012
Snowdon Inc., H2 2012
Marinus Pharmaceuticals, Inc., H2 2012
Nexgenix Pharmaceuticals, LLC, H2 2012
aFraxis Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Fragile X Syndrome Therapeutics – Drug Profile Updates
Fragile X Syndrome Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Fragile X Syndrome, H2 2012
Products under Development for Fragile X Syndrome – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
